Contents: Association between sexual and sub stance abuse/Treatment of catatonia with intra venous biperidene/Debt and deliberate self-harm/ Risk of HIV for women who inject drugs/ Dysphagiaintheneuroleptic malignantsyndrome/ Clozapine-induced neutropenia â€"¿ or not/Adinin istrative problems limiting electroconvulsive therapylB37 repeats are normal in most schizo phrenic patientsfFluvoxainineâ€"prescription event monitoringlDeath during alcohol withdrawal/ Glucocorticoids and the genesis of depressive illness/SSRIs to treat sexual dysfunction. Association between sexual and substance abuse Slit: Mullen et a! (BJP, December 1993, 163, 721â€" 732) in a community study of women again find an association between sexual abuse and various forms of psychopathology including drug and alcohol abuse. Research in the US with young substance abusers showed that up to 75% gave a history of abuse (Rohsenow, 1988). There appears to be no comparable British research. A small study on opiate addicts at a detoxifi cation unit in London was performed to estimate the prevalence of a history of sexual abuse. Forty STILLE, 0. & SAYERS, A. (1975) Die lmmobilisationsreaktion der Ratte als tierexperimentelles Modell für die Katatonie. Pharmacopsychiatry. 8, 105â€"1 14. WINTER, E. & GROSSE, R. (1979) Zur Wirkung von Biperiden bei akuten substuporos-stuporosen ZustSnden. Pharmacopsy chiatrv. 5, 383â€"387.
A double‐blind multicentre study was undertaken to compare the efficacy and safety of remoxipride in a controlled release (CR) formulation given once daily with haloperidol twice daily in patients with schizophrenic illness. In total, 114 patients were included. All were diagnosed as schizophrenic or schizophreniform according to DSM‐III. Their mean daily dose of remoxipride CR during the last week of treatment was 385 mg. In the haloperidol group the corresponding dose was 17 mg per day. The intended study period was 4 weeks with at least a one‐day washout. No significant differences were found between treatments regarding efficacy variables. The median total Brief Psychiatric Rating Scale (BPRS) score was 40 in the remoxipride CR group at start of treatment and 21 at last valid rating. For the haloperidol group the corresponding figures were 40 and 22. Treatment‐emergent extrapyramidal symptoms (Simpson and Angus rating) occurred statistically significantly more frequently and were more severe during haloperidol than during remoxipride CR treatment despite a statistically significantly higher concurrent use of anticholinergic drugs in the haloperidol group.
A double-blind multicentre study comparing the efficacy and safety of remoxipride in controlled-release formulation (REM-CR), given once a day, and immediate-release formulation (REM-IR) and haloperidol, given twice daily, was conducted in patients with schizophrenic illness. In total, 150 inpatients were randomized: 49, 51 and 50 in the REM-CR, REM-IR, and haloperidol groups, respectively. The mean daily dose of REM-CR during the last week of treatment was 361 mg, that of REM-IR 332 mg. In the haloperidol group the corresponding dose was 12.5mg per day. The study treatment period was four weeks. The median BPRS total score was 37.5 in the REM-CR group at start of treatment, and 14.5 at last rating (n = 38). For the REM-IR group and the haloperidol group the corresponding figures were 36.0 and 38.0 at start of treatment and 18.0 (n = 43) and 16.5 (n = 40) at last rating. No statistically significant differences were found between the treatments. Therapy-emergent extrapyramidal symptoms (Simpson & Angus rating scale) were significantly (p less than 0.05) more frequent and more severe during haloperidol than during REM-CR and REM-IR treatment, despite significantly higher concurrent use of anticholinergic drugs in the haloperidol group.--REM-CR was comparable in efficacy and tolerability to REM-IR. The tolerability profile favoured both remoxipride formulations over haloperidol. Evaluation of the clinical chemistry, haematology, and cardiovascular data showed no clinically significant deleterious effects on any organ system for either drug.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.